Co-polymeric hydrophilic nanospheres for drug delivery: Release kinetics, and cellular uptake

Indian Journal of Experimental Biology

Volumn 48, Issue 10, 2010, Pages 1043-1052

  Verma, Anita Kamra ^a   Chanchal, A ^a   Maitra, A ^b  

^a UNIVERSITY OF DELHI   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

Co polymeric nanospheres; Cytotoxicity; Hexyl carbamoyl fluorouracil (HCFU); Mia paca 3 human pancreatic cell line

Indexed keywords

1-HEXYLCARBAMOYL-5-FLUOROURACIL; ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; CARMOFUR; DRUG CARRIER; DRUG DERIVATIVE; FLUOROURACIL; N ISOPROPYLACRYLAMIDE; N-ISOPROPYLACRYLAMIDE; NANOSPHERE; POLYMER; POVIDONE;

ARTICLE; CHEMICAL PHENOMENA; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; TUMOR CELL LINE;

ACRYLAMIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; NANOSPHERES; POLYMERS; POVIDONE;

AGOUTI PACA;

EID: 78049462899     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hennink WE & Van Nostrum CF, Novel crosslinking methods to design hydrogels. Advanced Drug Delivery Reviews, 54, 1 (2002) 13.
2. Langer R S & Peppas NA, Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials, 2 (1981) 201.
3. Cicek H & Tuncel A, Immobilization of α-chymotrypsin in thermally reversible isopropylacrylamide copolymer gel, J Polym Sci, Part A Polym Chem, 36 (1998) 543.
4. Matsamura Y & Maeda H, A new concept for macro- molecular therapetics in cancer chemotherapy: mechanisms of tumorotropic accumulation of proteins and the anti-tumor agent SMANCS, Cancer Res, 46 (1986) 6387.
5. Davis S S, Biomedical applications of nano-technology- implications for drug targeting and gene therapy, TIBTEC, 15 (1997) 217.
6. Becouarn Y, Brunet R. & Barbe-Gaston C, Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary, Eur. J. Cancer Clin. Oncol, 25 (1989) 861.
7. Heidelberger C, Chudhuri N K, Dannerberg P, Dangnerberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer R J, Pleven E & Scheiner J, Fluorinated Pyrimidines, a New Class of Tumor-inhibitory Compounds, Nature, 79 (1957) 663.
8. Ansfield F J A less toxic fluorouracil dosage schedule, J Am Med Assoc, 190 (1964) 686.
9. Bateman J R, Pugh P R, Cassidy F R, Marshall G J & Irwin L E, 5-Fluorouracil given once weekly; Comparison of intravenous and oral administration, Cancer, 28 (1971) 907.
10. Bruckner H W & Creasy W A, The administration of 5-Fluorauracil by mouth, Cancer, 33 (1974) 14.
11. Fortuny I E, Theologides A & Kennedy B J, Hepatic arterial infusion for liver metastases from colon cancer, Cancer Chemother Reports (Part I), 59 (1975) 401.
12. Kaufman S,5-Fluorouracil in the treatment of gastrointestinal neoplasia, New England J Med, 288 (1973) 199.
13. Sadee W & Wong C G, Pharmacokinetics of 5-Fluorouracil: Inter-relationship with Biochemical kinetics in Monitoring Therapy, Clinical Pharmacokinetics, 2 (1977) 437.
14. Ozaki S, Ike Y, Mizuno H, Ishikawa K & Mori H, 5-Fluorouracil Derivatives I. The synthesis of 1 Carbamoy- 5-FU, Bull Chem Soc Japan, 50 (1977) 2406.
15. Raghava G P S, Goel A, Singh M A & Varshney G C, A simple microassay for computing the Haemolytic potency of the drugs, Biotechniques, 17 (1994) 1148.
16. Mosmann T, Rapid Calorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay, J Immunol Meth, 65 (1983) 55.
17. Verma A K, Sachin K, Saxena A & Bohidar H B, Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor-cycloheximide, for possible therapeutic applications, Curr Pharm Biotechnol, 6 (2005) 121.
18. Gupta A K, Madan S, Majumdar D K & Maitra A, Ketorolac entrappedin polymericmicelles:preparation, characterization and ocular anti-inflammatory studies, Int J Pharm, 209 (2001) 1.
19. Liu Z & Rimmer S, Synthesis and release of 5-FU from poly (N-vinylpyrrolidinone) bearing 5-FU derivatives, J Contro Rel, 81 (2002) 91.
20. Rosiak J M & Yoshii F, Hydrogels and their medical applications, Nucl Instrum methods Phys Res Sec B, 151 (1999) 56.
21. Galaev I Y & Mattiasson B, Smart polymers and what they could do in biotechnology and medicine, Trends Biotechnol, 17 (1999) 335.
22. Burr A & Bundgaard H, Prodrugs of 5-FU II: Hydrolysis Kinetics bio activation, solubility and lipophilicity of N-alkoxycarbomyl derivatives of 5-FU, Arch Pharm Chem Sci Ed, 12 (1984) 37.
23. Burr A & Bundgaard H, Prodrugs of 5-FU I: Hydrolysis Kinetics and physiochemical properties of various N-acyl derivatives of 5-FU, Int J Pharm, 21 (1984) 349.
24. Park K, Shalaby W S W & Park H, Biodegradable hydrogels for drug Delivery (Technomic, Basle) 1993.
25. Iigo M, Hoshi A, Nakamura A & Kuretani K, Antitumor Activity of 1-Hexylcarbamoyl-5-Fluorauracil in a variety Lewis of mouse tumors, Cancer Chemo & Pharma, 1 (1978) 203.
26. Hoshi A, Iigo M, Nakamura A, Yoshida M & Kuretani K, Anti-tumor activity of 1-Hexylcarbamoyl-5-Fluorauracil in a variety of experimental tumors, Gann, 67 (1976) 725.
27. Kim S W, Bae Y H & Okano T, Hydrogels: swelling, drug loading, and release, Pharm Res, 9 (1992) 283.
28. Satchi-Fainaro R, Mamluk R, Wang L, Short S M, Nagy J A, Feng D, Dvorak A M, Dvorak H F, Puder M & Folkman J, Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin,Cancer Cell, 7 (2005) 251.